LUDCI Magazine

  • Home
  • Ludci.eu
  • Headline Diplomat eMagazine
  • Submit Your News Article
  • Contact us
You are at :Home»Paid Articles»How Pharmaceuticals are gaining from COVID-19?

How Pharmaceuticals are gaining from COVID-19?

LUDCI.eu Editorial Team 08 Oct 2020 Paid Articles 2253 Views

Headline Diplomat eJournal – Issue 1, Series 2
The perilous lenses of COVID-19: The sociopolitical impact

Writes Edwin Oedipo, Content Writer, Headline Diplomat eJournal, LUDCI.eu

COVID-19 has brought an unprecedented health crisis around the world. People have lost their jobs and many economic spheres have been affected deeply. However, amidst this global epidemic, one industry is not only still standing, but gaining!

The Pharmaceutical field has experienced steady growth even as other businesses are making huge losses and some are closing. According to Technavio’s custom research reports, it is forecasted that the pharmaceutical logistics market will grow due to a rise in pharmaceutical sales. Companies like Eli Lily and Gilead, are observing a positive growth in the stock market.

Many countries around the globe have adjusted their resources and pumped them into their health sectors. Of course, they need pharmaceutical products to treat COVID-19. They must buy medicine, conduct tests and search for a vaccine.

Pfizer is one of the biggest gainers from the coronavirus outbreak. Pfizer’s pneumonia vaccine Prevnar 13 has seen an unforeseen rise in sales, presumptively because of the COVID-19, which in serious cases causes pneumonia with high mortality rates.

So far, no drug has been approved as the universal treatment for COVID-19 patients. Different countries around the world are using different drugs. Some of the drugs in use include hydroxychloroquine, remdesivir, tocilizumab, lopinavir, ACE inhibitors, etc.

Without a clear medicine for SARS-COV-2, people are being used as experiments and many have succumbed to death. Most of the drugs being used are still under laboratory studies gauging for their effectiveness. For instance, the Remdesivir drug is being used to treat COVID-19 symptoms in the US, EU, and Japan. Actually, it was approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), yet it’s under laboratory studies for its potency.

This indicates how pharmaceutical companies are being enriched at the expense of the people who fund them. Companies like Gilead, the creators of Remdesivir have had the most controversies of all drug companies fighting COVID-19. Remdesivir has been given the Compassionate Use Program (CUP) status and it is one of the top drugs battling COVID-19.

“Pharmaceutical companies view COVID-19 as a once-in-a-lifetime business opportunity,” said Gerald Posner, author of “Pharma: Greed, Lies, and the Poisoning of America.”  Yes, many pharmaceutical companies are working vigorously to come up with a vaccine and drugs that will rack up billions. As people around the world continue to suffer, pharmaceutical companies are getting richer.

Even as large pharmaceutical companies rush to find a COVID-19 vaccine and cure, the origin of the deadly virus is still a mystery. This raises more questions than answers as to whether the virus was manmade or different.

At first, there were question marks on whether face masks worked. Then, it was followed by questions marks about the accuracy of the tests. The most surprising incidence was when people who did not have any travel history or contact with COVID-19 patients tested positive.

From mid-February, there was a lot of hype and misleading information about Coronavirus. Some media houses went on to report true and untrue information about the virus as it ravaged one continent to another. This caused mayhem in many countries. Understanding the risk, United Nations Secretary-General Antonio Guterres, warned, “Our enemy is also growing surge misinformation”. He added, “The antidote to this pandemic of misinformation is fact-based news and analysis. It depends on media freedom and independent reporting”.

In places like America, coronavirus wiped out many black people by the end of April. In one of the interviews with the New York Times, Lori Lightfoot, the mayor of Chicago, said, “Those numbers take your breath away, they really do”. She was referring to the announced statistics of the outbreak in her city. African-Americans accounted for more than half of those who tested positive and 72 percent virus-related deaths in Chicago. This was on April 7.

Another scenario is the indigenous people of Brazil. The indigenous communities in the Amazon region and Brazil are in danger of being wiped out. In an interview with BBC News, Dr. Sofia Mendonca, a researcher at the Federal University of Sao Paulo, said, “There is an incredible risk of the virus spreading across the native communities and wiping them out”.

Newsguard noticed 191 websites in North America and Europe that have published wrong information about Coronavirus. Another study carried out by Reuters Institute discovered that 1/3 of social media users reported seeing false or misleading data about the virus.

When President Trump endorsed chloroquine and hydroxychloroquine as potential “game-changers” during one of his press conferences in March, it spurred many individuals and countries to stockpile the drugs. Countries like Algeria and Indonesia stockpiled the drug. Philippe Besset, who heads the main representative body of French pharmacists, the FSPF, said, “pharmacies had witnessed a surge in demand for hydroxychloroquine, marketed by pharmaceutical giant Sanofi under the trade name Plaquenil”. He also told France 24, “We’ve also witnessed a spike in the number of prescriptions for the drug”.

With all the unanswered questions about COVID-19, new drugs are still being experimented on different COVID-19 patients. Vaccine trials are also being rolled out and tests being done on a larger scale than it was 5 months ago.

Conclusion:

As lockdown restrictions are being eased and some economies slowly opening up, many people are hoping for a lasting solution. But the question still lingers – is COVID-19 a manmade virus to reduce certain populations or is it aimed at enriching pharmaceutical companies? As long as the origin of COVID-19 is still unknown, there will always be questions to answer.

Photo by cottonbro, Pexels

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
covid 19 EMA FDA misleading information patients pharma pharmaceutical companies WHO 2020-10-08
LUDCI.eu Editorial Team
Tags covid 19 EMA FDA misleading information patients pharma pharmaceutical companies WHO

Related Articles

AI Revolution: Transforming Industries in Italy

AI Revolution: Transforming Industries in Italy

LUDCI.eu Editorial Team 08 Aug 2024
Media Reporting on Human Trafficking

Media Reporting on Human Trafficking

LUDCI.eu Editorial Team 11 Nov 2020
COVID-19 restrictions, vaccination campaigns and dirty politics

COVID-19 restrictions, vaccination campaigns and dirty politics

LUDCI.eu Editorial Team 26 Feb 2021

Article Countdown

  • August 2026 (3)
  • July 2026 (3)
  • June 2026 (3)
  • May 2026 (3)
  • April 2026 (5)
  • March 2026 (4)
  • February 2026 (2)
  • January 2026 (4)
  • December 2025 (3)
  • November 2025 (3)
  • October 2025 (4)
  • September 2025 (4)
  • July 2025 (4)
  • June 2025 (3)
  • May 2025 (4)
  • April 2025 (3)
  • March 2025 (6)
  • February 2025 (8)
  • January 2025 (4)
  • December 2024 (3)
  • November 2024 (3)
  • October 2024 (3)
  • September 2024 (2)
  • August 2024 (2)
  • July 2024 (3)
  • June 2024 (6)
  • May 2024 (9)
  • April 2024 (6)
  • March 2024 (10)
  • February 2024 (5)
  • January 2024 (9)
  • December 2023 (10)
  • November 2023 (6)
  • October 2023 (7)
  • September 2023 (4)
  • August 2023 (5)
  • July 2023 (5)
  • June 2023 (8)
  • May 2023 (6)
  • April 2023 (4)
  • March 2023 (6)
  • February 2023 (6)
  • January 2023 (2)
  • December 2022 (5)
  • October 2022 (2)
  • September 2022 (4)
  • August 2022 (3)
  • July 2022 (2)
  • June 2022 (3)
  • May 2022 (1)
  • April 2022 (5)
  • March 2022 (8)
  • February 2022 (4)
  • January 2022 (5)
  • November 2021 (1)
  • October 2021 (1)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (4)
  • June 2021 (6)
  • May 2021 (6)
  • April 2021 (2)
  • March 2021 (5)
  • February 2021 (3)
  • January 2021 (6)
  • December 2020 (9)
  • November 2020 (9)
  • October 2020 (17)
  • September 2020 (28)
  • August 2020 (11)


Total Articles: 357

Menu

Home

About Us

eMagazine

Services

Menu

Book Our Services

Courses

LUDCI Foundation

Reach & Donate

Social Media

Facebook X Instagram LinkedIn YouTube

Send us an email at info@ludci.eu

Call for Proposals

Call for Proposals
Copyright © 2026 Luxembourg's Diplomacy and Communications Institute SaRL (LUDCI.eu). All rights reserved. Unauthorized reproduction, transmission, or alteration of any material is prohibited without prior written permission. For inquiries, please contact us.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag(\'js\', new Date()); gtag(\'config\', \'UA-168083100-2\');
SAVE & ACCEPT